{ "items": [ "\n\n
\n \n 11 March 2022\n \n
\n\n \n \n \n\n \n \n \nIn the UK, every 5 days a baby is born with SMA. Treatments are available now. If these treatments are delivered at birth, these newborns have the best chance of living long and healthy lives. If treated later, when they are identified because of the symptoms, they may survive, but with a severe disability. So, for every 5 days that a newborn screening is delayed, a baby in the UK loses the chance of a brighter future. \r\nOxford University is initiating a population-based newborn screening study in the Thames Valley. This study aims to make it possible to detect SMA within days of birth, before symptoms develop, so that any affected newborn can receive diagnosis and treatment at the earliest possible opportunity. We hope that it will pave the way for a national newborn screening that will save about 70 babies/year in the UK from disability
\n \n\n\n \n 10 March 2022\n \n
\n\n \n \n \n\n \n \n \nScientists are investigating how to treat pain in babies who can\u2019t tell you when it hurts.
\n \n\n\n \n 28 February 2022\n \n
\n\n \n \n \n\n \n \n \nMore than 3 years after construction commenced, IDRM is proud to announce that the IMS-Tetsuya Nakamura Building, which houses the new Institute, at Old Road Campus has been completed.
\n \n\n\n \n 3 December 2021\n \n
\n\n \n\n \n\n \n \n \n \n Neuromuscular Diseases\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n \n \nThings that seemed impossible, only a few years ago, are happening today. The first patient in Europe and one of the first in the world was injected with a potential treatment, GTX-102, in a phase I/II clinical trial in Oxford.
\n \n\n\n \n 30 November 2021\n \n
\n\n \n \n \n\n \n \n \nThe Department of Paediatrics at the University of Oxford - a world leader in child health research, has launched a new brand identity.
\n \n\n\n \n 25 November 2021\n \n
\n\n \n\n \n\n \n \n \n \n Haematology\n \n \n \n \n Publication\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n \n \nThe breakthrough could lead to development of new treatments for infant Acute Lymphoblastic Leukaemia.
\n \n\n\n \n 12 November 2021\n \n
\n\n \n\n \n\n \n \n \n \n Children's Health\n \n \n \n \n Neuroimaging\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n \n \nFor decades physicians believed that premature babies didn\u2019t experience pain. Here\u2019s what doctors know now \u2013 and the innovative solutions being embraced by today's caregivers.
\n \n\n\n \n 8 November 2021\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Research\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n \n \nThe University of Oxford and Brazilian Ministry of Health have announced a joint initiative to set up a global health and clinical research unit in Brazil led by Professor Sue Ann Clemens CBE.
\n \n\n\n \n 5 October 2021\n \n
\n\n \n\n \n\n \n \n \n \n Children's Health\n \n \n \n \n Haematology\n \n \n \n \n Immunology\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n \n \nA new study published this week in Nature, provides the most detailed analysis so far of the prenatal development of blood and immune cells in the bone marrow.
\n \n\n\n \n 16 September 2021\n \n
\n\n \n\n \n\n \n \n \n \n Haematology\n \n \n \n \n Publication\n \n \n\n \n\n\n
\n \n\n \n \n \nA new paper published this week in Cell Reports reveals that changes in the gene expression of blood stem cells occur across the human lifetime; an important step in the understanding and treatment of blood disorders.
\n \n\n\n \n 23 August 2021\n \n
\n\n \n\n \n\n \n \n \n \n Neuromuscular Diseases\n \n \n \n \n Publication\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n \n \nResearch led by Carlo Rinaldi and Catheryn Lim discovered that a naturally-occurring isoform of an androgen receptor can be used in therapy for spinal and bulbar muscular atrophy, and shows potential for other diseases.
\n \n\n\n \n 20 August 2021\n \n
\n\n \n\n \n\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n \n \nThe Oxford-run VALIDATE Network has received $1.5 million in funding for its tuberculosis vaccine work from the Bill & Melinda Gates Foundation.
\n \n\n\n \n 9 August 2021\n \n
\n\n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n \n \nDr Samantha Vanderslott (Oxford Vaccine Group) and Dr Claas Kirchhelle (University College Dublin) have had their three-year project \u2018Typhoid, Cockles, and Terrorism\u2019 about the history of typhoid in Dublin successfully funded.
\n \n\n\n \n 29 July 2021\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n \n \nThe University of Oxford\u2019s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca\u2019s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.
\n \n\n\n \n 27 July 2021\n \n
\n\n \n\n \n\n \n \n \n \n Clinical Trials\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n \n \nResearchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.
\n \n\n\n \n 9 July 2021\n \n
\n\n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n COVID-19\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n \n \nResearchers behind the Oxford AstraZeneca coronavirus vaccine have been recognised for their excellence at a healthcare awards ceremony.
\n \n\n\n \n 8 July 2021\n \n
\n\n \n\n \n\n \n \n \n \n Public Engagement\n \n \n \n \n Publication\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n \n \n'Brain Fever', a new book by internationally-renowned medical scientist Professor Richard Moxon, describes the decades of research that contribute to the development of vaccines for life-threatening illnesses such as meningitis, and how immunisation has been our greatest public health intervention.
\n \n\n\n \n 30 June 2021\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Clinical Trials\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n \n \nAlternating doses of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against COVID-19, according to researchers running the University of Oxford-led Com-COV study.
\n \n\n\n \n 28 June 2021\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Clinical Trials\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n \n \nResearch on the ChAdOx1 nCoV-19, also known as the Oxford-AstraZeneca vaccine, indicates that a long interval between first and second doses does not compromise the immune response after a late second dose.
\n \n\n\n \n 28 June 2021\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Clinical Trials\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n \n \nThe University of Oxford in partnership with AstraZeneca began vaccinations on 27 June 2021 for a new phase in human trials to test a COVID-19 vaccine \u2018AZD2816\u2019 in volunteers against the B.1.351 variant of concern \u2013 commonly known as the Beta variant.
\n \n\n